CAGT hero 2

Leaders in Developing and Applying Genomic Technologies

The Genomic Revolution promises the discovery of targeted approaches for treating disease. Innovations like CRISPR-based genome editing and comprehensive epigenomic profiling can inform, streamline and accelerate drug target discoveries, but piecing together this complex puzzle requires an interdisciplinary approach.

The Center for Advanced Genomic Technologies (CAGT) has assembled a team of world-leading engineers, scientists and physicians to integrate these technologies to unravel disease biology and discover new drug targets. By working together, we will catalyze a more robust biotechnology enterprise.

In the News

Aravind Asokan

November 30, 2022 | Duke School of Medicine

Aravind Asokan to Lead Partnership with Danaher Corporation to Accelerate Gene Therapy Breakthroughs 

Aravind Asokan will lead a new strategic partnership with Danaher Corporation to form the first Danaher Beacon for Gene Therapy Innovation, a new initiative designed to access breakthrough science to create technologies and applications that will improve human health.

Charlie Gersbach

November 16, 2022 | Duke Research Blog

Gersbach Among Most Cited Scientists

Gersbach is one of 30 Duke faculty to make this year's list

Aravind Asokan

November 11, 2022 | Cision PR Newswire

Danaher Launches Beacon Initiative and Its First Partnership Focused on Gene Therapy Innovation

Danaher Corporation (NYSE: DHR), a global science and technology innovator, today announced that it has entered a strategic partnership with Duke University to form its first Danaher Beacon for Gene Therapy Innovation.